Dr. Gerald Falchook, MD
Claim this profileSarah Cannon Research Institute at HealthONE
Expert in Tumors
Expert in Solid Tumors
38 reported clinical trials
59 drugs studied
Area of expertise
1Tumors
Global LeaderStage IV
Stage III
HPV negative
2Solid Tumors
Global LeaderStage IV
Stage III
RET positive
Affiliated Hospitals
Clinical Trials Gerald Falchook, MD is currently running
CAB-ROR2-ADC + PD-1 Inhibitor
for Breast Cancer
This trial is testing a new targeted cancer treatment called CAB-ROR2-ADC in patients with advanced solid tumors. The drug seeks out cancer cells with a specific marker and delivers a potent treatment directly to them.
Recruiting1 award Phase 1 & 29 criteria
Oral NKT2152
for Kidney Cancer
This trial is testing NKT2152, a new oral drug, in adults with a specific type of kidney cancer who have no other treatment options. It aims to find the safest dose and see if the drug can effectively fight the cancer.
Recruiting1 award Phase 1 & 213 criteria
More about Gerald Falchook, MD
Clinical Trial Related5 years of experience running clinical trials · Led 38 trials as a Principal Investigator · 20 Active Clinical TrialsTreatments Gerald Falchook, MD has experience with
- Pembrolizumab
- Nivolumab
- Docetaxel
- Gemcitabine
- PD-1 Inhibitor
- TSR-022
Breakdown of trials Gerald Falchook, MD has run
Tumors
- Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab
- Engineered T-Cell Therapy for Advanced Cancer
- An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma
Solid Tumors
Non-Small Cell Lung Cancer
- Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab
- CAB-ROR2-ADC + PD-1 Inhibitor for Breast Cancer
- BT8009 + Pembrolizumab for Solid Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Gerald Falchook, MD specialize in?
Gerald Falchook, MD focuses on Tumors and Solid Tumors. In particular, much of their work with Tumors has involved Stage IV patients, or patients who are Stage III.
Is Gerald Falchook, MD currently recruiting for clinical trials?
Yes, Gerald Falchook, MD is currently recruiting for 20 clinical trials in Denver Colorado. If you're interested in participating, you should apply.
Are there any treatments that Gerald Falchook, MD has studied deeply?
Yes, Gerald Falchook, MD has studied treatments such as Pembrolizumab, Nivolumab, Docetaxel.
What is the best way to schedule an appointment with Gerald Falchook, MD?
Apply for one of the trials that Gerald Falchook, MD is conducting.
What is the office address of Gerald Falchook, MD?
The office of Gerald Falchook, MD is located at: Sarah Cannon Research Institute at HealthONE, Denver, Colorado 80218 United States. This is the address for their practice at the Sarah Cannon Research Institute at HealthONE.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.